DRKS00029638已完成不适用
Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany - SEMVAc
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15,813
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Male
入选标准
- •Inclusion criteria for vaccine group:
- •- Age = 18 years
- •- Existing informed consent
- •- Men and trans* persons who have sex with changing men (MSM) and/or trans* persons (according to the STIKO recommendation for indication vaccination with MVA-BN against monkeypox).
- •Inclusion criteria for control group:
- •- Age = 18 years
- •- Informed consent available
- •- Men and trans* persons who have sex with changing men (MSM) and/or trans* persons (according to the STIKO recommendation for indication vaccination with MVA-BN against monkeypox).
- •Inclusion criteria for subgroup:
- •- Inclusion in the vaccine group or control group
- •- Existing indication for regular blood sampling
排除标准
- •- Inability to consent
- •- Known exposure to MPXV before 1st vaccination (post-exposure prophylaxis).
- •- For the subgroup of individuals with serological testing: Presence of medical reasons against the collection of additional blood volume.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of the effectiveness of vaccination with 2009 H1N1 vaccines during influenza season 2010-112009 H1N1-influenssarokotteiden tehokkuus influenssakaudella 2010-11 - Pandemiarokotuskampanjan jatkotutkimusInfluenza caused by the 2009 H1N1 influenza virus (swine influenza)MedDRA version: 12.1Level: LLTClassification code 10022001Term: Influenza (epidemic)EUCTR2010-021033-30-FIational Institute for Health and Welfare3,000
尚未招募
3 期
Immunogenicity and safety after vaccinated with BBIBP-CorV (COVID-19 vaccine) in Thai pregnant womePregnant womenCOVID-19SARS-CoV-2 vaccineVaccinePregnantBBIBP-CorVSinopharmTCTR20210923013Chulabhorn Hospital400
已完成
不适用
Evaluation of efficacy and risks of vaccination for liver transplant recipientsiver transplant recipientsJPRN-UMIN000030485Kyoto University200
进行中（未招募）
不适用
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of AgePEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused by Haemophilus influenzae type b), as a booster dose administered to toddlers previously primed with three doses of a hexavalent vaccine.EUCTR2006-000898-30-DESanofi Pasteur Incorporated
已完成
不适用
Safety and efficacy of live attenuated vaccine in patients received hematopoietic stem cell transplantatioRecipients of hematopoietic stem cell transplantationJPRN-UMIN000016500Fukkuoka Blood and Marrow Transplantation Group300